-

Candel Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference

NEEDHAM, Mass.--(BUSINESS WIRE)--Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Executive Officer, will present an overview of the Company at the upcoming Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 PM ET.

About Candel Therapeutics

Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what we believe to be a systemic immune response against locally injected tumors and their distant metastases. To learn more, visit www.candeltx.com.

Contacts

Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
heidi.chokeir@canalecomm.com
619-203-5391

Candel Therapeutics, Inc.


Release Versions

Contacts

Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
heidi.chokeir@canalecomm.com
619-203-5391

More News From Candel Therapeutics, Inc.

Candel Therapeutics Appoints Diem Nguyen, Ph.D., M.B.A., to Its Board of Directors

NEEDHAM, Mass.--(BUSINESS WIRE)--Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed Diem Nguyen, Ph.D., M.B.A., to its Board of Directors. The Company also announced that Carrie S. Cox will be stepping down as Chairman and member of the Board of Directors, effective immediately, due to a limitation on the number of her public company board commitments, and will continue to serve as a Speci...

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

NEEDHAM, Mass.--(BUSINESS WIRE)--Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced initial results from an ongoing Phase 1 clinical trial of its oncolytic virus, CAN-3110, in patients with high-grade glioma (HGG) that has recurred after initial treatment. The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annu...

Candel Therapeutics Names Carrie S. Cox as Chairman of its Board of Directors

NEEDHAM, Mass.--(BUSINESS WIRE)--Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Carrie S. Cox has been named Chairman of the Board of Directors, effective immediately. Paul Manning, the outgoing Chairman, will continue to serve as a Director. Ms. Cox has had an eminent career in the biopharmaceutical industry, both in operating roles and as a corporate director. She is currently the Chairman of Or...
Back to Newsroom